Micropattern differentiation of mouse pluripotent stem cells recapitulates embryo regionalized cell fate patterning

  1. Sophie M Morgani
  2. Jakob J Metzger
  3. Jennifer Nichols
  4. Eric D Siggia  Is a corresponding author
  5. Anna-Katerina Hadjantonakis  Is a corresponding author
  1. Memorial Sloan Kettering Cancer Center, United States
  2. Rockefeller University, United States
  3. University of Cambridge, United Kingdom

Abstract

During gastrulation epiblast cells exit pluripotency as they specify and spatially arrange the three germ layers of the embryo. Similarly, human pluripotent stem cells (PSCs) undergo spatially organized fate specification on micropatterned surfaces. Since in vivo validation is not possible for the human, we developed a mouse PSC micropattern system and, with direct comparisons to mouse embryos, reveal the robust specification of distinct regional identities. BMP, WNT, ACTIVIN and FGF directed mouse epiblast-like cells to undergo an epithelial-to-mesenchymal transition and radially pattern posterior mesoderm fates. Conversely, WNT, ACTIVIN and FGF patterned anterior identities, including definitive endoderm. By contrast, epiblast stem cells, a developmentally advanced state, only specified anterior identities, but without patterning. The mouse micropattern system offers a robust scalable method to generate regionalized cell types present in vivo, resolve how signals promote distinct identities and generate patterns, and compare mechanisms operating in vivo and in vitro and across species.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Sophie M Morgani

    Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Jakob J Metzger

    Center for Studies in Physics and Biology, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Jennifer Nichols

    Wellcome Trust-MRC Center for Stem Cell Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Eric D Siggia

    Center for Studies in Physics and Biology, Rockefeller University, New York, United States
    For correspondence
    siggiae@mail.rockefeller.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7482-1854
  5. Anna-Katerina Hadjantonakis

    Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States
    For correspondence
    hadj@mskcc.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7580-5124

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084391)

  • Anna-Katerina Hadjantonakis

National Cancer Institute (P30CA008748)

  • Anna-Katerina Hadjantonakis

Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD080699)

  • Eric D Siggia

National Science Foundation (PHY1502151)

  • Eric D Siggia

Wellcome

  • Sophie M Morgani

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experimentation: All mice used in this study were maintained in accordance withthe guidelines of the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Animal Care and Use Committee (IACUC) under protocol number 03-12-017 (PI Hadjantonakis).

Reviewing Editor

  1. Martin Pera, University of Melbourne, Australia

Version history

  1. Received: October 16, 2017
  2. Accepted: February 2, 2018
  3. Accepted Manuscript published: February 7, 2018 (version 1)
  4. Version of Record published: February 9, 2018 (version 2)
  5. Version of Record updated: February 12, 2019 (version 3)

Copyright

© 2018, Morgani et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,858
    Page views
  • 1,486
    Downloads
  • 122
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sophie M Morgani
  2. Jakob J Metzger
  3. Jennifer Nichols
  4. Eric D Siggia
  5. Anna-Katerina Hadjantonakis
(2018)
Micropattern differentiation of mouse pluripotent stem cells recapitulates embryo regionalized cell fate patterning
eLife 7:e32839.
https://doi.org/10.7554/eLife.32839

Share this article

https://doi.org/10.7554/eLife.32839

Further reading

    1. Immunology and Inflammation
    2. Stem Cells and Regenerative Medicine
    Jesus A Castor-Macias, Jacqueline A Larouche ... Carlos A Aguilar
    Research Article Updated

    The acute traumatic or surgical loss of skeletal muscle, known as volumetric muscle loss (VML), is a devastating type of injury that results in exacerbated and persistent inflammation followed by fibrosis. The mechanisms that mediate the magnitude and duration of the inflammatory response and ensuing fibrosis after VML remain understudied, and as such, the development of regenerative therapies has been limited. To address this need, we profiled how lipid mediators, which are potent regulators of the immune response after injury, varied with VML injuries that heal or result in fibrosis. We observed that non-healing VML injuries displayed increased pro-inflammatory eicosanoids and a lack of pro-resolving lipid mediators. Treatment of VML with a pro-resolving lipid mediator synthesized from docosahexaenoic acid, called Maresin 1, ameliorated fibrosis through reduction of neutrophils and macrophages and enhanced recovery of muscle strength. These results expand our knowledge of the dysregulated immune response that develops after VML and identify a novel immuno-regenerative therapeutic modality in Maresin 1.

    1. Stem Cells and Regenerative Medicine
    J Barney Bryson, Alexandra Kourgiantaki ... Linda Greensmith
    Research Article

    Breakdown of neuromuscular junctions (NMJs) is an early pathological hallmark of amyotrophic lateral sclerosis (ALS) that blocks neuromuscular transmission, leading to muscle weakness, paralysis and, ultimately, premature death. Currently, no therapies exist that can prevent progressive motor neuron degeneration, muscle denervation, or paralysis in ALS. Here, we report important advances in the development of an optogenetic, neural replacement strategy that can effectively restore innervation of severely affected skeletal muscles in the aggressive SOD1G93A mouse model of ALS, thus providing an interface to selectively control the function of targeted muscles using optical stimulation. We also identify a specific approach to confer complete survival of allogeneic replacement motor neurons. Furthermore, we demonstrate that an optical stimulation training paradigm can prevent atrophy of reinnervated muscle fibers and results in a tenfold increase in optically evoked contractile force. Together, these advances pave the way for an assistive therapy that could benefit all ALS patients.